Today’s cyclodextrin:
Gilead Sciences announced that it will donate approximately 5,000 vials of remdesivir to the Rwanda Medical Supply in conjunction with the Ministry of Health of the Republic of Rwanda and the Africa Centers for Disease Control for emergency use in response to the Marburg Virus Disease (MVD) outbreak.
Not many know, yet Veklury (SBECD+remdesivir), which was the first drug approved against Covid-19, was originally developed against the Marburg virus and later also saved the lives of Ebola-infected people.
Remdesivir is being provided for the treatment of MVD in Rwanda for emergency use. Remdesivir is not approved for the treatment of MVD anywhere globally, and the safety and efficacy of this use is not known.
Remdesivir is a nucleotide analog prodrug invented and developed by Gilead, building on more than a decade of the company’s antiviral research. Remdesivir has broad-spectrum antiviral activity both in vitro and in animal models against multiple viral pathogens, including Marburg, Ebola, SARS, MERS and SARS-CoV-2, the virus that causes COVID-19.
Remdesivir has been approved as a COVID-19 treatment in approximately 50 countries worldwide. To date, remdesivir has been made available to more than 14 million patients around the world, including more than 8 million people in middle- and low-income countries through Gilead’s voluntary licensing program.
Gilead Donates Remdesivir for Emergency Use in Response to Marburg Virus Disease in Rwanda
